Marc O. Williams

Davis Polk advised V.F. Corporation in connection with the spinoff of its wholly owned subsidiary, Kontoor Brands, Inc., into an independent, publicly traded company through a tax-free…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk is advising Morgan Stanley on its $900 million acquisition of Solium Capital Inc. The transaction is expected to close in the second quarter of 2019, subject to shareholder and…

Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its divestment agreement with PT Indonesia Asahan Aluminium (Persero) (“Inalum”) in connection with Inalum’s acquisition…

Davis Polk is advising Tyson Foods, Inc. on its $2.16 billion acquisition of the Keystone Foods business from Marfrig Global Foods. The transaction, which is expected to close in mid-fiscal…

Davis Polk is advising VF Corporation on its separation into two independent, publicly traded companies: VF Corporation, a global apparel and footwear powerhouse, and a yet-to-be named…

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…

Davis Polk is advising VF Corporation on its sale of the Nautica® brand business to Authentic Brands Group (ABG), LLC. The transaction, which is expected to close in the first half of 2018,…

Davis Polk is advising VF Corporation on its acquisition of the Altra footwear brand from ICON Health & Fitness, Inc. The transaction, which is expected to close in April 2018, is…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…